Liquidia Corporation Common Stock vs SPDR Kensho Final Frontiers ETF — how do they compare? Liquidia Corporation Common Stock trades at $33.46 (market cap $2.40B), while SPDR Kensho Final Frontiers ETF trades at $100.25 (market cap $167.17M). The key difference: Liquidia Corporation Common Stock is far larger — about 14.4× SPDR Kensho Final Frontiers ETF's market cap, and SPDR Kensho Final Frontiers ETF is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and SPDR Kensho Final Frontiers ETF for 14 Days on average.
| LQDA | ROKT | |
|---|---|---|
Market Cap | $2.40B | $167.17M |
Volume | 2,857,547 | 167,750 |
Sector | Health | Sector/Thematic |
52-Week High | $91.03 | $136.68 |
52-Week Low | $22.02 | $72.93 |
Typical Hold Time | 0 Days | 14 Days |
Enterprise Value | $2.30B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ROKT (SPDR S&P Kensho Final Frontiers ETF) trades at $101.88, down 1.0% today, with a bearish technical outlook showing 17 sell signals versus 2 buy signals. The ETF provides diversified exposure to aerospace and defense companies, though key financial ratios are currently unavailable. Recent news highlights growing investor interest in space-related investments through diversified vehicles like ROKT rather than individual space stocks.
The ETF offers efficient exposure to the final frontiers theme but faces challenges from high operational costs and profitability timelines in the space sector. Current bearish technical indicators suggest near-term pressure, while long-term growth potential in aerospace and defense remains supported by industry developments.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →SPDR Kensho Final Frontiers ETF seeks exposure to companies supporting exploration of outer space and the deep sea. Its holdings include businesses involved in aerospace, defense, communications, research, and related technologies.
Read more on ROKT →